WO2009027736A3 - 2,4 diaminopyrimid'lnes for the treatment of myeloproliferative disorders and cancer - Google Patents

2,4 diaminopyrimid'lnes for the treatment of myeloproliferative disorders and cancer Download PDF

Info

Publication number
WO2009027736A3
WO2009027736A3 PCT/GB2008/050739 GB2008050739W WO2009027736A3 WO 2009027736 A3 WO2009027736 A3 WO 2009027736A3 GB 2008050739 W GB2008050739 W GB 2008050739W WO 2009027736 A3 WO2009027736 A3 WO 2009027736A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
treatment
diaminopyrimid
lnes
myeloproliferative disorders
Prior art date
Application number
PCT/GB2008/050739
Other languages
French (fr)
Other versions
WO2009027736A2 (en
Inventor
Stephanos Ioannidis
Michelle Lamb
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Ltd
Stephanos Ioannidis
Michelle Lamb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Astrazeneca Uk Ltd, Stephanos Ioannidis, Michelle Lamb filed Critical Astrazeneca Ab
Publication of WO2009027736A2 publication Critical patent/WO2009027736A2/en
Publication of WO2009027736A3 publication Critical patent/WO2009027736A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

The present invention relates to compounds of Formula (I) and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds provide a treatment for myeloproliferative disorders and cancer.
PCT/GB2008/050739 2007-08-27 2008-08-27 2,4 diaminopyrimid'lnes for the treatment of myeloproliferative disorders and cancer WO2009027736A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96828207P 2007-08-27 2007-08-27
US60/968,282 2007-08-27

Publications (2)

Publication Number Publication Date
WO2009027736A2 WO2009027736A2 (en) 2009-03-05
WO2009027736A3 true WO2009027736A3 (en) 2009-04-23

Family

ID=40303514

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/050739 WO2009027736A2 (en) 2007-08-27 2008-08-27 2,4 diaminopyrimid'lnes for the treatment of myeloproliferative disorders and cancer

Country Status (1)

Country Link
WO (1) WO2009027736A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8501936B2 (en) 2009-06-05 2013-08-06 Cephalon, Inc. Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
MX337662B (en) 2010-10-06 2016-03-14 Glaxosmithkline Llc Benzimidazole derivatives as pi3 kinase inhibitors.
CN103649074B (en) * 2011-07-07 2016-05-11 默克专利股份公司 Be used for the treatment of the azacyclo-of the replacement of cancer
EP2554544A1 (en) * 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
CN104114543B (en) * 2012-01-06 2019-03-15 安吉奥斯医药品有限公司 Therapeutical active compound and its application method

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040214814A1 (en) * 2000-12-21 2004-10-28 David Bebbington Pyrazole compounds useful as protein kinase inhibitors
WO2006074057A2 (en) * 2004-12-30 2006-07-13 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
WO2006115452A1 (en) * 2005-04-27 2006-11-02 Astrazeneca Ab Use of pyrazolyl-pyrimidine derivatives in the treatment of pain
WO2006123113A2 (en) * 2005-05-16 2006-11-23 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040214814A1 (en) * 2000-12-21 2004-10-28 David Bebbington Pyrazole compounds useful as protein kinase inhibitors
WO2006074057A2 (en) * 2004-12-30 2006-07-13 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
WO2006115452A1 (en) * 2005-04-27 2006-11-02 Astrazeneca Ab Use of pyrazolyl-pyrimidine derivatives in the treatment of pain
WO2006123113A2 (en) * 2005-05-16 2006-11-23 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WANG TAO ET AL: "Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinases.", JOURNAL OF MEDICINAL CHEMISTRY 14 AUG 2008, vol. 51, no. 15, 14 August 2008 (2008-08-14), pages 4672 - 4684, XP002514102, ISSN: 1520-4804 *

Also Published As

Publication number Publication date
WO2009027736A2 (en) 2009-03-05

Similar Documents

Publication Publication Date Title
WO2009016410A3 (en) Chemical compounds 831
MX2010013682A (en) Tricyclic 2,4-diamin0-l,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders.
WO2009013545A3 (en) Chemical compounds
PT2150530E (en) Substituted sulfonamide derivatives
WO2009155121A3 (en) Inhibitors of pi3 kinase
WO2012016186A8 (en) Macrocyclic kinase inhibitors and uses thereof
WO2007135527A3 (en) Benzimidazolyl compounds
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
WO2006123113A3 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
WO2007138472A3 (en) Triazolopyridazine derivatives
MY141220A (en) Pyrazole derivatives as inhibitors of receptor tyrosine kinases
WO2005080352A3 (en) Quinazoline derivatives and therapeutic use thereof
MY147890A (en) 9-(pyrazol-3-yl)-9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidaz0 [4,5-b] pyridin-5-amine derivatives and their use for the treatment of cancer
WO2012048129A3 (en) Inhibitors of polo-like kinase
WO2011058027A3 (en) N-9-substituted purine compounds, compositions and methods of use
WO2007109279A3 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
TW200626158A (en) Naphthaline derivatives
WO2009071690A3 (en) 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressine-dependent diseases
WO2006077024A3 (en) 5-aminoindole derivatives
WO2008128009A3 (en) Aminopyrimidines useful as kinase inhibitors
WO2013040227A3 (en) Therapeutic compounds
WO2008020306A3 (en) Isoindole derivatives
MX2009006010A (en) Amine derivatives and their use in beta-2-adrenoreceptor mediated diseases.
WO2010121675A3 (en) Thiazolyl-benzimidazoles

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08788710

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08788710

Country of ref document: EP

Kind code of ref document: A2